Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.
about
Trial Watch:: Oncolytic viruses for cancer therapyImmune cells: more than simple carriers for systemic delivery of oncolytic viruses.Phase I trial of Seneca Valley Virus (NTX-010) in children with relapsed/refractory solid tumors: a report of the Children's Oncology Group.Oncolytic Poxviruses.Defining Effective Combinations of Immune Checkpoint Blockade and Oncolytic VirotherapySafety and biodistribution of a double-deleted oncolytic vaccinia virus encoding CD40 ligand in laboratory BeaglesChimeric antigen receptor-engineered T cells as oncolytic virus carriers.Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies.A cancer-favoring oncolytic vaccinia virus shows enhanced suppression of stem-cell like colon cancer.Oncolytic Virus-Mediated Targeting of PGE2 in the Tumor Alters the Immune Status and Sensitizes Established and Resistant Tumors to Immunotherapy.A killer choice for cancer immunotherapy.Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.Activity of a group B oncolytic adenovirus (ColoAd1) in whole human blood.Combination of E2F-1 promoter-regulated oncolytic adenovirus and cytokine-induced killer cells enhances the antitumor effects in an orthotopic rectal cancer model.Oncolytic Virotherapy and the Tumor Microenvironment.Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.Anti-colorectal cancer effects of anti-p21Ras scFv delivered by the recombinant adenovirus KGHV500 and cytokine-induced killer cells
P2860
Q27021951-414FEF09-1224-461C-B2B8-F6EC5305E3F4Q35162284-04C6ADB4-70FF-4EE7-BC13-082FCF16D1DBQ35224606-60C5B1B4-55CC-42CB-A36A-1DFEE2C030F7Q35234349-C0CB50E3-0CFD-4D1F-B343-6235D4C860D1Q36378248-AD268E86-62F0-4FE9-A15F-5903A87CBC9AQ36664201-6E7C02B8-D6BF-414E-899C-C72AA1050D41Q36664258-FF026E1D-F42A-4F78-BB5D-A75B82C63728Q36796025-7252C387-C0B3-4CAF-8B34-95CAA0BA8A99Q37086063-72DD1626-4C9E-405C-9E62-7DEE1499852BQ37129177-974954EE-6574-4A33-809A-9C39210B0884Q38208944-ABD9F35E-D982-450F-ACA4-E2D608449795Q41706961-C4590B64-EDC9-4D97-AC2C-621B279B91F7Q42236177-6713118F-4F8D-49A3-B065-647EF2CEB4A9Q42269490-DB9CEEC0-2407-49B9-ADA4-EA9576574923Q47560690-FDF521B0-5767-4131-9B57-53396E0683FDQ52699883-BD41F1FB-DC62-4C5A-A49F-C45D98800DA2Q59127505-1E0FAA79-6794-497C-AB1C-2B9C1691BB39
P2860
Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Crosstalk between immune cell ...... ficking and antitumor effects.
@ast
Crosstalk between immune cell ...... ficking and antitumor effects.
@en
type
label
Crosstalk between immune cell ...... ficking and antitumor effects.
@ast
Crosstalk between immune cell ...... ficking and antitumor effects.
@en
prefLabel
Crosstalk between immune cell ...... ficking and antitumor effects.
@ast
Crosstalk between immune cell ...... ficking and antitumor effects.
@en
P2093
P2860
P356
P1433
P1476
Crosstalk between immune cell ...... ficking and antitumor effects.
@en
P2093
David L Bartlett
Hannah Chen
Padma Sampath
Steve H Thorne
Weizhou Hou
P2860
P304
P356
10.1038/MT.2012.257
P577
2012-12-11T00:00:00Z